Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxAspirin: New Insights Into Its Mechanism of Interaction With Cancer
/in Drug repurposing, Preclinical Research/by MaxZebrafish Embryo miRNAs: A Potential New Approach to Slow or Stop Cancer Spread
/in Not PCa related, Preclinical Research/by MaxQED-203 Moving Closer to Clinical Trials for mCRPC
/in Preclinical Research/by MaxPositive Results From Phase 3 Trial of CAN-2409 for Localized Prostate Cancer Led to RMAT Designation
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxUPDATE: Phase 1b Data for ORIC-944 in Combination with AR Inhibitors in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by Max